Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Alnylam Pharmaceuticals and MIT have developed new nanoparticles for the systemic delivery of RNAi therapeutics. They created core-shell nanoparticles using high-throughput polymer synthesis and then screened for those having the best properties for intracellular delivery. “Continued progress in delivery of RNAi therapeutics requires broad-based efforts around novel lipids, conjugates, and polymers,” says Kevin Fitzgerald, Alnylam’s senior director of research. The partners published their findings in the Proceedings of the National Academy of Sciences USA (DOI: 10.1073/pnas.1106379108).
This article has been sent to the following recipient: